Table 2.
hESC Lines Used for Production of Cell Products Used in Clinical Trials So Far
| hESC Line (Provider) | hESC Line (hPSCreg) | First Publication of Cell Line | No. of Clinical Trials |
|---|---|---|---|
| MA09 | ACTe002-A | 2006 | 11 |
| Cyt49 | VCYTe001-A | 2006 | 4 |
| H1 | WAe001-A | 1998 | 3 |
| H9 | WAe009-A | 1998 | 2 |
| Shef-1 | AXORe001-A | 2004 | 2 |
| HADC102 | HADe008-A | 2012 | 1 |
| HADC100 | HADe007-A | 2012 | 1 |
| I6 | TECHe003-A | 2002 | 1 |
| Q-CTS-hESC-2 | not yet registered | 2016 | 1 |
| RC-09 | RCe013-A | 2012 | 1 |
| Data NA | 5 |
Given are the provider's and hPSCreg's designation of hESC lines, the year of its first publication in the scientific literature, and the number of clinical trials based on the respective cell line. Please note that for five studies performed in China, cell line information cannot be provided.